The Cardiorenal Protective Effects of Low-Dose Tolvaptan in Peritoneal Dialysis Patients with Volume Overload
American Journal of Nephrology · 2026-10-08 · 1-1
DOI: 10.1159/ajn/ablag013 ↗Abstract
Introduction: The aims of the study were to compare the efficacy and safety of low-dose tolvaptan versus conventional therapy in peritoneal dialysis (PD) patients with volume overload and to evaluate its effects on cardiac and renal functions. Methods: The control group received conventional therapy, while the tolvaptan group received oral tolvaptan (15 mg) every other day for 6 months. Clinical and safety data were collected at baseline, 3, 6, and 9 months (3 months post-discontinuation). Primary outcomes included changes in volume status, residual renal function, and cardiac function. Results: Sixty patients with PD who underwent regular follow-up at the Second Hospital of Jilin University between May 1, 2023, and December 31, 2025, were randomized 1:1 to tolvaptan or control (n = 30 each); 56 completed follow-up (28 per group). Overhydration decreased in both groups, with a greater reduction in the tolvaptan group (linear trend test, p = 0.033). A 24-h urine volume in the tolvaptan group increased during the first week (p = 0.02) and remained higher throughout the treatment period (all p < 0.05), although total water removal (urine volume plus peritoneal ultrafiltration volume) did not differ between the 2 groups at any follow-up time point (all p > 0.05). A 24-h peritoneal ultrafiltration in the tolvaptan group showed an initial decrease, followed by an increase. Residual renal glomerular filtration rate (GFR) in the tolvaptan group remained stable at 3 and 6 months (p = 0.695, p = 0.178), but decreased after discontinuation (p < 0.001), whereas in the control group, residual renal GFR was lower than baseline at all time points (p < 0.05). Ln (BNP) levels declined in both groups (p = 0.392). The left ventricular ejection fraction in the tolvaptan group increased during the first 6 months (p = 0.019) but decreased at 9 months, with no change in controls. Ln (LVMI) decreased in the tolvaptan group but increased in the control group, with a significant difference in trends (p < 0.001). One patient had hypernatremia, which resolved, no other adverse events. During the follow-up period, no episodes of PD-related peritonitis, PD technique failure, or all-cause mortality were observed in either group. Conclusion: With strict sodium monitoring, low-dose tolvaptan safely improved volume status and delayed residual renal function decline. It also showed potential cardioprotective effects, primarily reflected by a reduction in LVMI. However, the long-term effects on hard clinical outcomes, including mortality and technique survival, require further investigation.
EUVIMED